A Bimetallic Nanomodulator to Reverse Immunosuppression via Sonodynamic‐Ferroptosis and Lactate Metabolism Modulation
Small · 2024
DOI: 10.1002/smll.202404580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Xi Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai…. Hauptthemen laut MEDLINE: Ferroptosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) responds poorly to immunotherapy due to insufficient immunogenicity and highly immunosuppressive tumor microenvironment (TME). Herein, an intelligent calcium/cobalt‐based nanomodulator (Ca,Co)CO 3 ‐LND‐TCPP@F127‐TA (abbreviated as CCLT@FT) is developed to act as a sonodynamic‐ferroptosis inducer and metabolic immunoadjuvant to enhance anti‐tumor immunotherapy. More details, simultaneous reactive oxygen species (ROS) generation and glutathione (GSH) depletion can be achieved due to the existence of Co 2+ /Co 3+ redox couple in CCLT@FT. Meanwhile, mitochondrial Ca 2+ overload and tetrakis(4‐carboxyphenyl) porphyrin (TCPP)‐mediated sonodynamic therapy (SDT) further amplify the oxidative stress and promote ferroptosis in tumor cells. More impressively, CCLT@FT can modulate lactate metabolism by doping with cobalt and loading with lonidamine (LND, an inhibitor of MCT4), thereby reversing the high‐lactate immunosuppressive TME. Furthermore, the combination with immune checkpoint blockade (ICB) therapy is found to achieve superior anti‐tumor immunity, which in turn promotes ferroptosis of tumor cells by downregulating SLC7A11 protein, ultimately creating a “cycle” therapy. Overall, this work demonstrates a novel strategy for enhancing anti‐tumor immunotherapy based on a closed‐loop enhancement therapeutic route between CCLT@FT inducing ferroptosis/lactate metabolism modulation and ICB therapy, providing an alternative and important reference for effective immunotherapy of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai, 200050, P. R. China.
- Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing, 100049, P. R. China.
- School of Chemistry and Materials Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, P. R. China.
ORCID-Profile: Hangrong Chen
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Sailing Program
- Shanghai Science International Cooperation Project
Zitieren
APA
Deng, X., Zhu, Y., Dai, Z., Liu, Q., Song, Z., Liu, T., Huang, Y., & Chen, H. (2024). A Bimetallic Nanomodulator to Reverse Immunosuppression via Sonodynamic‐Ferroptosis and Lactate Metabolism Modulation. Small. https://doi.org/10.1002/smll.202404580
Vancouver
Deng X, Zhu Y, Dai Z, Liu Q, Song Z, Liu T, et al. A Bimetallic Nanomodulator to Reverse Immunosuppression via Sonodynamic‐Ferroptosis and Lactate Metabolism Modulation. Small. 2024. doi:10.1002/smll.202404580
BibTeX
@article{Deng2024,
author = {Deng, Xi and Zhu, Yutong and Dai, Zideng and Liu, Qing and Song, Ze and Liu, Tianzhi and Huang, Yuefeng and Chen, Hangrong},
title = {A Bimetallic Nanomodulator to Reverse Immunosuppression via Sonodynamic‐Ferroptosis and Lactate Metabolism Modulation},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202404580}
}
EUVIMED